Thu. Sep 21st, 2023

Brussels, 28 February 2023

The European Commission has approved, under the EU Merger Regulation, the acquisition of joint control of Neopharmed Holding S.p.A. (‘Neopharmed’) of Italy, by NB Renaissance Partners Holdings S.à.r.l. (‘NBRPH’) of Luxembourg, Ardian France S.A. (‘Ardian’) of France and Mediolanum Farmaceutici S.p.A. (‘Mediolanum’) of Italy.

Neopharmed commercialises finished dose pharmaceuticals and supplements in various therapeutic areas, as well as medical devices and cosmetics. NBRPH is part of the Neuberger Berman group, which provides a broad range of investment solutions. Ardian is a private equity company that manages a number of investment funds. Mediolanum is active, through its subsidiaries, in the pharmaceutical and contract manufacturing organisation sectors.

The Commission concluded that the proposed acquisition would raise no competition concerns, given that the parties’ activities do not compete in the supply of finished dose pharmaceuticals. In addition, the Commission found that the parties would not have the ability or the incentive to engage in foreclosure practices. The transaction was examined under the normal merger review procedure.

More information is available on the Commission’s competition website, in the public case register under the case number M.10997.

Source – EU Commission



Forward to your friends
GDPR Cookie Consent with Real Cookie Banner